Review





Similar Products

anti spp1  (MedChemExpress)
93
MedChemExpress anti spp1
A Identification of four celltypes in the LLC TME by scRNA-seq. <t>B</t> <t>Anti-SPP1</t> therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.
Anti Spp1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spp1/Osteopontin+Antibody/pmc13161377-406-37-43
Average 93 stars, based on 1 article reviews
anti spp1 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
spp1 expression  (Galectin Therapeutics)
86
Galectin Therapeutics spp1 expression
A Identification of four celltypes in the LLC TME by scRNA-seq. <t>B</t> <t>Anti-SPP1</t> therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.
Spp1 Expression, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spp1/pm42302972-124-7-2
Average 86 stars, based on 1 article reviews
spp1 expression - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
spp1 mφs  (Galectin Therapeutics)
86
Galectin Therapeutics spp1 mφs
A Identification of four celltypes in the LLC TME by scRNA-seq. <t>B</t> <t>Anti-SPP1</t> therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.
Spp1 Mφs, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spp1/pm42302972-125-1-1
Average 86 stars, based on 1 article reviews
spp1 mφs - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
spp1  (Affinity Biosciences)
86
Affinity Biosciences spp1
A Identification of four celltypes in the LLC TME by scRNA-seq. <t>B</t> <t>Anti-SPP1</t> therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.
Spp1, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spp1/anti+egr1+targeting/pm42231460-61-43-47
Average 86 stars, based on 1 article reviews
spp1 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
spp1  (Yeasen Biotechnology)
86
Yeasen Biotechnology spp1
A Identification of four celltypes in the LLC TME by scRNA-seq. <t>B</t> <t>Anti-SPP1</t> therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.
Spp1, supplied by Yeasen Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spp1/spp1/pm42162902-63-26-30
Average 86 stars, based on 1 article reviews
spp1 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
human osteopontin (opn) quantikine elisa kit  (Bio-Techne corporation)
95
Bio-Techne corporation human osteopontin (opn) quantikine elisa kit
A Identification of four celltypes in the LLC TME by scRNA-seq. <t>B</t> <t>Anti-SPP1</t> therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.
Human Osteopontin (Opn) Quantikine Elisa Kit, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spp1/Human+Osteopontin+(OPN)+Quantikine+ELISA+Kit/bio-techne+corporation___dost00
Average 95 stars, based on 1 article reviews
human osteopontin (opn) quantikine elisa kit - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
recombinant human osteopontin (opn) protein  (Bio-Techne corporation)
95
Bio-Techne corporation recombinant human osteopontin (opn) protein
A Identification of four celltypes in the LLC TME by scRNA-seq. <t>B</t> <t>Anti-SPP1</t> therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.
Recombinant Human Osteopontin (Opn) Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spp1/Recombinant+Human+Osteopontin+(OPN)+Protein/bio-techne+corporation___1433-op
Average 95 stars, based on 1 article reviews
recombinant human osteopontin (opn) protein - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
spp1  (OriGene)
94
OriGene spp1
A Identification of four celltypes in the LLC TME by scRNA-seq. <t>B</t> <t>Anti-SPP1</t> therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.
Spp1, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spp1/Spp1+(NM_009263)+Mouse+Tagged+ORF+Clone/10__1016_slash_j__jpha__2026__101679-138-17-19
Average 94 stars, based on 1 article reviews
spp1 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
jo urn al pr e p roo f 10 antibodies targeting spp1  (Affinity Biosciences)
86
Affinity Biosciences jo urn al pr e p roo f 10 antibodies targeting spp1
A Identification of four celltypes in the LLC TME by scRNA-seq. <t>B</t> <t>Anti-SPP1</t> therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.
Jo Urn Al Pr E P Roo F 10 Antibodies Targeting Spp1, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spp1/anti+egr1+targeting/10__1016_slash_j__jpha__2026__101679-93-11-23
Average 86 stars, based on 1 article reviews
jo urn al pr e p roo f 10 antibodies targeting spp1 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
spp1  (Sema4 Inc)
86
Sema4 Inc spp1
A Identification of four celltypes in the LLC TME by scRNA-seq. <t>B</t> <t>Anti-SPP1</t> therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.
Spp1, supplied by Sema4 Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spp1/integrins+spp1/bio_rxiv__64898__2026__04__27__719870-85-10-18
Average 86 stars, based on 1 article reviews
spp1 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


A Identification of four celltypes in the LLC TME by scRNA-seq. B Anti-SPP1 therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.

Journal: NPJ Precision Oncology

Article Title: Multi-omics profiling reveals tumor microenvironment characteristics linked to immunotherapy response and prognosis in non-small cell lung cancer

doi: 10.1038/s41698-026-01474-2

Figure Lengend Snippet: A Identification of four celltypes in the LLC TME by scRNA-seq. B Anti-SPP1 therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.

Article Snippet: Five days post-inoculation, mice with palpable tumors were randomly assigned to four treatment groups ( n = 4 per group) using a random number table : Control (PBS) , Anti-PD-1 (clone RMP1-14, Bio X Cell, #BE0146) , Anti-SPP1 (anti-mouse osteopontin antibody, clone 103D6, MCE), and Anti-SPP1 combined with Anti-PD-1.

Techniques: Control, Immunofluorescence